The Role of TLRs in Anti-cancer Immunity and Tumor Rejection
Zuzanna Urban‐WójciukInternational Centre for Cancer Vaccine Science (ICCVS), University of Gdaǹsk, Gdaǹsk, PolandMohd M. KhanUniversity of Maryland School of Medicine, Baltimore, MD, United StatesBenjamin L. OylerUniversity of Maryland School of Medicine, Baltimore, MD, United StatesRobin FåhræusInternational Centre for Cancer Vaccine Science (ICCVS), University of Gdaǹsk, Gdaǹsk, PolandNatalia Marek-TrzonkowskaLaboratory of Immunoregulation and Cellular Therapies, Department of Family Medicine, Medical University of Gdaǹsk, Gdaǹsk, PolandAleksandra Nita‐LazarNational Institute of Allergy and Infectious DiseasesTed R. HuppMasaryk Memorial Cancer InstituteDavid R. GoodlettInternational Centre for Cancer Vaccine Science (ICCVS), University of Gdaǹsk, Gdaǹsk, Poland
2019en
ABI
Annotatsiya
In recent years, a lot of scientific interest has focused on cancer immunotherapy. Although chronic inflammation has been described as one of the hallmarks of cancer, acute inflammation can actually trigger the immune system to fight diseases, including cancer. Toll-like receptor (TLR) ligands have long been used as adjuvants for traditional vaccines and it seems they may also play a role enhancing efficiency of tumor immunotherapy. The aim of this perspective is to discuss the effects of TLR stimulation in cancer, expression of various TLRs in different types of tumors, and finally the role of TLRs in anti-cancer immunity and tumor rejection.
Hali tarjima qilinmagan
Identifikatorlar
Iqtiboslar va manbalar
2 ta iqtibos0 ta foydalanilgan manba